123 related articles for article (PubMed ID: 3261688)
41. The formation of complexes between human plasminogen activator inhibitor-1 (PAI-1) and sodium dodecyl sulfate: possible implication in the functional properties of PAI-1.
Gaussem P; Anglés-Cano E
Biochim Biophys Acta; 1991 Sep; 1079(3):321-9. PubMed ID: 1911857
[TBL] [Abstract][Full Text] [Related]
42. Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1.
Strömqvist M; Andersson JO; Boström S; Deinum J; Ehnebom J; Enquist K; Johansson T; Hansson L
Protein Expr Purif; 1994 Aug; 5(4):309-16. PubMed ID: 7950376
[TBL] [Abstract][Full Text] [Related]
43. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells.
Schleef RR; Wagner NV; Loskutoff DJ
J Cell Physiol; 1988 Feb; 134(2):269-74. PubMed ID: 3257967
[TBL] [Abstract][Full Text] [Related]
44. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.
Mikus P; Urano T; Liljeström P; Ny T
Eur J Biochem; 1993 Dec; 218(3):1071-82. PubMed ID: 7506655
[TBL] [Abstract][Full Text] [Related]
45. Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women.
Häggroth L; Mattsson C; Felding P; Nilsson IM
Thromb Res; 1986 Jun; 42(5):585-94. PubMed ID: 3087015
[TBL] [Abstract][Full Text] [Related]
46. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
47. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Takeuchi T; Niiya K; Kubonishi I; Miyoshi I
Thromb Haemost; 1990 Apr; 63(2):259-64. PubMed ID: 2363126
[TBL] [Abstract][Full Text] [Related]
48. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression.
Konkle BA; Ginsburg D
J Clin Invest; 1988 Aug; 82(2):579-85. PubMed ID: 3136192
[TBL] [Abstract][Full Text] [Related]
49. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
[TBL] [Abstract][Full Text] [Related]
50. Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta.
Philips M; Juul AG; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1986 Apr; 55(2):213-7. PubMed ID: 2424117
[TBL] [Abstract][Full Text] [Related]
51. Large scale, rapid purification of recombinant tissue-type plasminogen activator.
Dodd I; Jalalpour S; Southwick W; Newsome P; Browne MJ; Robinson JH
FEBS Lett; 1986 Dec; 209(1):13-7. PubMed ID: 3100325
[TBL] [Abstract][Full Text] [Related]
52. Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies.
Nielsen LS; Lecander I; Andreasen PA; Henschen A; Astedt B; Danø K
Thromb Res; 1987 May; 46(3):411-23. PubMed ID: 2440126
[TBL] [Abstract][Full Text] [Related]
53. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.
Ginsburg D; Zeheb R; Yang AY; Rafferty UM; Andreasen PA; Nielsen L; Dano K; Lebo RV; Gelehrter TD
J Clin Invest; 1986 Dec; 78(6):1673-80. PubMed ID: 3097076
[TBL] [Abstract][Full Text] [Related]
54. Analysis of binding protein for tissue-type plasminogen activator in human endothelial cells.
Fukao H; Hagiya Y; Nonaka T; Okada K; Matsuo O
Biochem Biophys Res Commun; 1992 Sep; 187(2):956-62. PubMed ID: 1326962
[TBL] [Abstract][Full Text] [Related]
55. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3.
Heeb MJ; España F; Geiger M; Collen D; Stump DC; Griffin JH
J Biol Chem; 1987 Nov; 262(33):15813-6. PubMed ID: 2824468
[TBL] [Abstract][Full Text] [Related]
56. Messenger RNA for plasminogen activator inhibitor.
Sawdey M; Ny T; Loskutoff DJ
Thromb Res; 1986 Jan; 41(2):151-60. PubMed ID: 3485834
[TBL] [Abstract][Full Text] [Related]
57. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D
Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173
[TBL] [Abstract][Full Text] [Related]
58. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
Masson C; Angles-Cano E
Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
[TBL] [Abstract][Full Text] [Related]
59. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI-1).
MacGregor IR; Booth NA
Thromb Haemost; 1988 Feb; 59(1):68-72. PubMed ID: 3129808
[TBL] [Abstract][Full Text] [Related]
60. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.
Lindahl TL; Ohlsson PI; Wiman B
Biochem J; 1990 Jan; 265(1):109-13. PubMed ID: 2105714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
